Intrinsiqq
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. Insider Trading

SGMT

Compare
Last 12 months

Insiders sold $4.62M and bought nothing on the open market.

85% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Mar 2024.

Net open-market
−$4.62M
0 buys · 9 sales
Under a 10b5-1 plan
85%
of the value sold
Insiders who bought / sold
0 / 5
executives and directors
Last open-market buy
Mar 2024
Mar 26, 2024

Get an email when SGMT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Aug 1410b5-1 plan
    George Kemble
    Director · sold 350,987 at $10.23
    $3.59M
    85% of stake
  • Aug 1110b5-1 plan
    George Kemble
    Director · sold 20,206 at $9.95
    201K
    25% of stake
  • Jul 20No plan
    David Happel
    President & CEO · sold 64,051 at $7.76
    497K
    8.0% of stake
  • Jul 20No plan
    Elizabeth Rozek
    Chief Legal & Admin. Officer · sold 10,545 at $7.76
    82K
    4.5% of stake
  • Jul 2010b5-1 plan
    George Kemble
    Director · sold 18,844 at $7.46
    141K
    23% of stake
  • Feb 10No plan
    David Happel
    President & CEO · sold 12,101 at $5.36
    65K
    1.8% of stake
  • Feb 10No plan
    Thierry Chauche
    Chief Financial Officer · sold 1,312 at $5.36
    7K
    7.7% of stake
  • Feb 10No plan
    Eduardo Bruno Martins
    Chief Medical Officer · sold 3,640 at $5.36
    20K
    3.4% of stake
  • Feb 10No plan
    Elizabeth Rozek
    Chief Legal & Admin. Officer · sold 2,622 at $5.36
    14K
    1.4% of stake
  • Nov 20, 202510b5-1 plan
    George Kemble
    Executive Chairman · sold 37,688 at $7.69
    290K
    32% of stake
  • Jul 21, 2025No plan
    David Happel
    President & CEO · sold 65,478 at $9.13
    598K
    8.7% of stake
  • Jul 21, 2025No plan
    Eduardo Bruno Martins
    Chief Medical Officer · sold 8,277 at $9.13
    76K
    7.2% of stake
  • Jul 21, 2025No plan
    Elizabeth Rozek
    General Counsel and CCO · sold 10,780 at $9.13
    98K
    5.5% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SGMT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SGMT

CompareIntrinsic value
ORMPOramed Pharmaceuticals Inc.
$3.57-3.25%35
DNTHDianthus Therapeutics Inc.
$84.55-0.33%10
CYCNCyclerion Therapeutics Inc.
$35.45+6.55%40
MCRBSeres Therapeutics, Inc.
$1.24-6.77%0
NWBONorthwest Biotherapeutics Inc.
$0.13-7.86%30
SCPXScorpius Holdings Inc.
$0.00+0.00%10
CPMDCannapharmaRx Inc.
$0.00+0.00%24
LPCNLipocine Inc.
$1.50+0.00%40

Held by ETFs

SGMT is in 13 US ETFs. The largest of them, with SGMT's weight in each:

Spot a number that looks wrong? Check it in SGMT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing SGMT

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.